Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 dose-finding study in grass pollen allergic rhinitis
2011-003368-64Phase 2Completed
- Sponsor
- Biomay AG
- Start
- Sep 2011
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BM32 in grass pollen allergy and allergic rhinitis (AR) (4 arms), sponsored by Biomay AG. Primary endpoint: Change in total Nasal Symptom Score. Started Sep 2011; status: completed.
02
Drugs
BM32
03
Conditions
grass pollen allergyallergic rhinitis (AR)
Beyond the preview
Go deeper on 2011-003368-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003368-64.